Real-world effectiveness and safety of simnotrelvir/ritonavir for COVID-19: A nationwide, multicenter, prospective, observational cohort study in China
Authors:
- Bing HanBHBing Han
- Chunling DuCDChunling Du
- Min DengMDMin Deng
- Renhong TangRTRenhong Tang
- Jianping DongJDJianping Dong
- Xu SongXSXu Song
- Yunfeng QiaoYQYunfeng Qiao
- Zheng NiZNZheng Ni
- WenJie YangWYWenJie Yang
- Jiankun YangJYJiankun Yang
- Tianxin XiangTXTianxin Xiang
- Yan HuangYHYan Huang
Open Access
- 7 November 2024
- journal article
- research article
- Published by Elsevier in Journal of Infection
- Vol. 89 (6)
Abstract
No abstract availableKeywords
Funding Information
- Beijing Municipal Health Commission (2022-01-02)
- National Key Research and Development Program of China (2023YFC3043400)
This publication has 18 references indexed in Scilit:
- Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19New England Journal of Medicine, 2024
- Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvirNature Communications, 2023
- A first-in-human phase 1 study of simnotrelvir, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjectsEuropean Journal of Pharmaceutical Sciences, 2023
- Deuremidevir and Simnotrelvir–Ritonavir for the Treatment of COVID-19ACS Pharmacology & Translational Science, 2023
- Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational studyThe Lancet, 2022
- Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in Shanghai Omicron waveEmerging Microbes & Infections, 2022
- Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID StudyThe Lancet, 2022
- Combined and interactive effects of alcohol drinking and cigarette smoking on the risk of severe illness and poor clinical outcomes in patients with COVID-19: a multicentre retrospective cohort studyPublic Health, 2022
- Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern AfricaNature, 2022
- Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodiesNature, 2021